Nomura Holdings Inc Intellia Therapeutics, Inc. Transaction History

Nomura Holdings Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $184,366 - $253,871	7,740 New	7,740 $212,000
Q2 2023 Aug 14, 2023	SELL	$34.58 - $46.03 $6.42 Million - $8.54 Million	-185,555 Reduced 50.07%	185,033 $7.55 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $6.61 Million - $8.89 Million	-198,364 Reduced 34.86%	370,588 $13.8 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $13.3 Million - $25 Million	399,175 Added 235.12%	568,952 $19.8 Million
Q3 2022 Nov 15, 2022	BUY	$53.92 - $71.7 $9.15 Million - $12.2 Million	169,777 New	169,777 $9.52 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $370,636 - $494,984	-2,800 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $29.3 Million - $78 Million	-481,816 Reduced 99.42%	2,800 $453,000
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $22.6 Million - $40.6 Million	484,616 New	484,616 $38.9 Million
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $196,585 - $663,253	-10,440 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$17.47 - $24.93 $2.15 Million - $3.07 Million	-123,260 Reduced 92.19%	10,440 $210,000
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $1.49 Million - $3.06 Million	133,700 New	133,700 $2.81 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.